M
Metrion Biosciences
Delivering a range of high quality ion channel drug discovery services
About Metrion Biosciences
Metrion Biosciences operates as a specialized contract research organization (CRO) focused on preclinical drug discovery, with a core expertise in ion channel research. The company was established in 2015 as a spin-out from Xention, a biopharmaceutical firm, and is based at Granta Park in Cambridge, UK. Its foundation is built upon the extensive experience of its management team in ion channel drug discovery, originally assembled at Xention. The founding leadership team includes Dr. Keith McCullagh, who served as the initial Chairman, Dr. Andrew Southan as Chief Operating Officer (now Chief Executive Officer), and Dr. Marc Rogers as Chief Scientific Officer. Dr. Southan's background includes significant roles at companies like Celltech and BioFocus DPI, bringing over 25 years of experience in ion channel research and drug discovery. Similarly, Dr. Rogers has a long-standing career in the field, contributing to the progression of multiple compounds into clinical development.
The firm provides a suite of services to the pharmaceutical and biotechnology industries on a fee-for-service or collaborative basis. Its business model centers on delivering high-quality, validated ion channel and GPCR screening services. Metrion's offerings are critical for drug discovery programs, particularly in areas such as neuroscience, cardiovascular disease, and pain. The company's services are designed to help clients identify potential drug candidates and assess their safety and efficacy at an early stage. This includes cardiac safety screening, which is crucial for regulatory requirements and involves assays like the hERG screening and the Comprehensive in Vitro Proarrhythmia Assay (CiPA) panel. Additionally, Metrion conducts neuroscience assays, investigating targets for conditions like Alzheimer's, Parkinson's, and multiple sclerosis, as well as neurotoxicology testing.
Metrion utilizes a range of advanced platform technologies to deliver its services. These include high-throughput automated and conventional patch clamp electrophysiology, which allows for detailed analysis of ion channel function. The company also employs high-quality cell lines and offers translational assays to better predict how a drug will behave in humans. A significant milestone for the company was securing a £2.7 million investment in its second funding round to expand its facilities and services, and later receiving further funding of £3.7 million in 2021, led by Gresham House Ventures. This financial backing has enabled the company to grow its team, enhance its technological capabilities, and expand its global client base, which includes major pharmaceutical companies in the UK, USA, and Japan.
Source: Dealroom company dataNews
Open roles
Metrion Biosciences in the Great Abington ecosystem
The Metrion Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
O2h Ventures
Gresham House Ventures
Series B and later1 investor entered at this stage
Maven Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Metrion Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Metrion Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


